TP53 in bone and soft tissue sarcomas
Genomic and functional study of existing and emerging sarcoma targets, such as fusion
proteins, chromosomal aberrations, reduced tumor suppressor activity, and oncogenic …
proteins, chromosomal aberrations, reduced tumor suppressor activity, and oncogenic …
Therapeutic advances in leiomyosarcoma
K Lacuna, S Bose, M Ingham, G Schwartz - Frontiers in Oncology, 2023 - frontiersin.org
Leiomyosarcoma is an aggressive mesenchymal malignancy and represents one of the
most common subtypes of soft tissue sarcomas. It is characterized by significant disease …
most common subtypes of soft tissue sarcomas. It is characterized by significant disease …
Pan-Cancer Analysis of BRCA1 and BRCA2 Genomic Alterations and Their Association With Genomic Instability as Measured by Genome-Wide Loss of …
ES Sokol, D Pavlick, H Khiabanian… - JCO precision …, 2020 - ascopubs.org
PURPOSE BRCA1 or BRCA2 loss of function results in homologous recombination
deficiency (HRD), which is targetable by poly (ADP-ribose) polymerase (PARP) inhibitors …
deficiency (HRD), which is targetable by poly (ADP-ribose) polymerase (PARP) inhibitors …
Phase II study of olaparib and temozolomide for advanced uterine leiomyosarcoma (NCI Protocol 10250)
M Ingham, JB Allred, L Chen, B Das… - Journal of Clinical …, 2023 - ascopubs.org
PURPOSE Uterine leiomyosarcoma (uLMS) is an aggressive subtype of soft-tissue sarcoma
with frequent metastatic relapse after curative surgery. Chemotherapy provides limited …
with frequent metastatic relapse after curative surgery. Chemotherapy provides limited …
Genomic database analysis of uterine leiomyosarcoma mutational profile
Uterine Leiomyosarcoma (uLMS) is by far the most common type of uterine sarcoma,
characterized by an aggressive clinical course, a heterogeneous genetic profile and a very …
characterized by an aggressive clinical course, a heterogeneous genetic profile and a very …
Comprehensive review of uterine leiomyosarcoma: pathogenesis, diagnosis, prognosis, and targeted therapy
Q Yang, OS Madueke-Laveaux, H Cun, M Wlodarczyk… - Cells, 2024 - mdpi.com
Uterine leiomyosarcoma (uLMS) is the most common subtype of uterine sarcomas. They
have a poor prognosis with high rates of recurrence and metastasis. The five-year survival …
have a poor prognosis with high rates of recurrence and metastasis. The five-year survival …
Clinical utility of CDK4/6 inhibitors in sarcoma: successes and future challenges
PURPOSE Soft tissue and bone sarcomas are rare malignancies that exhibit significant
pathologic and molecular heterogeneity. Deregulation of the CDKN2A-CCND-CDK4/6 …
pathologic and molecular heterogeneity. Deregulation of the CDKN2A-CCND-CDK4/6 …
Hyper-Dependence on NHEJ Enables Synergy between DNA-PK Inhibitors and Low-Dose Doxorubicin in Leiomyosarcoma
Purpose: Leiomyosarcoma (LMS) is an aggressive sarcoma for which standard
chemotherapies achieve response rates under 30%. There are no effective targeted …
chemotherapies achieve response rates under 30%. There are no effective targeted …
Targeting homologous recombination deficiency in uterine leiomyosarcoma
G Dall, CJ Vandenberg, K Nesic, G Ratnayake… - Journal of Experimental …, 2023 - Springer
Background Uterine leiomyosarcoma (uLMS) is a rare and aggressive gynaecological
malignancy, with individuals with advanced uLMS having a five-year survival of< 10 …
malignancy, with individuals with advanced uLMS having a five-year survival of< 10 …
Homologous recombination repair deficiency as a therapeutic target in sarcoma
Sarcoma is a rare cancer arising from soft tissue and bone and consists of more than 50
distinct subtypes. There is an increasing emphasis on understanding the cancer biology of …
distinct subtypes. There is an increasing emphasis on understanding the cancer biology of …